PSEN1 Gene Alteration May Be Early Biomarker for Alzheimer’s, Study Suggests

PSEN1 Gene Alteration May Be Early Biomarker for Alzheimer’s, Study Suggests
A specific chemical alteration present in the presenilin1 (PSEN1) gene may be a biomarker for earlier Alzheimer's disease (AD) diagnosis and treatment response monitoring, a study suggests. The modification, called DNA methylation, was observed both in brain samples of Alzheimer's mouse models and post-mortem brain tissue of Alzheimer's patients. It was also measurable in blood samples from patients with late-onset AD, suggesting its detection is a new, non-invasive way to diagnose the illness. The study, "CpG and non-CpG Presenilin1 methylation pattern in course of neurodevelopment and neurodegeneration is associated with gene expression in human and murine brain," was published in Epigenetics. Genetics are thought to play a central role in the development of Alzheimer's, with the PSEN1 gene being identified as one of the genes that may be linked to the development of the disease. In addition to mutations in certain genes, epigenetic changes may also play a role in Alzheimer's. These are changes in gene activity that do not involve the alteration of the DNA sequence itself and are often induced by environmental factors, such as diet an
Subscribe or to access all post and page content.